Drug Development for Cancer and Diabetes
A Path to 2030
1st Edition
Published on 28. February 2022
Book
Paperback/Softback
362 pages
978-1-77463-493-6 (ISBN)
Description
Key features include:
Details the role of plants for the treatment and management of cancer and diabetes
Discusses the role of phytocompounds as ligands for cancer and diabetic targets
Reviews plants and the potential of phytochemicals as antidiabetic and anticancer drugs
Explores the green biosynthesis of nanoparticles and their treatment efficiency
Details the role of plants for the treatment and management of cancer and diabetes
Discusses the role of phytocompounds as ligands for cancer and diabetic targets
Reviews plants and the potential of phytochemicals as antidiabetic and anticancer drugs
Explores the green biosynthesis of nanoparticles and their treatment efficiency
Reviews / Votes
"This book extrapolates the recent advancements, emerging trends, and novel innovations and speculates about the future perspective in the discovery of drugs for the treatment of cancer and diabetes. As a complete package for the readers, this book provides a valuable window on the revolutionary sector of drug discovery. Part I and Part II of the book together provides comprehensive content to understand the theoretical aspect as well as practical advances and research discoveries. The novel approach of depicting the role of plants and the potential of phytochemi?cals as antidiabetic and anticancer drugs is a key feature."-From the Foreword by Dr. P. Padmanabhan, Deputy Director, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
More details
Language
English
Place of publication
Oakville
Canada
Target group
College/higher education
Professional and scholarly
Academic and Postgraduate
Illustrations
32 s/w Abbildungen, 13 farbige Abbildungen, 31 s/w Tabellen
31 Tables, black and white; 13 Illustrations, color; 32 Illustrations, black and white
Dimensions
Height: 234 mm
Width: 156 mm
Weight
640 gr
ISBN-13
978-1-77463-493-6 (9781774634936)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Other editions
Additional editions
K. Saravanan | Chukwuebuka Egbuna | Horne Iona Averal
Drug Development for Cancer and Diabetes
A Path to 2030
Book
08/2020
1st Edition
Apple Academic Press Inc.
€206.50
Shipment within 3-4 weeks
K. Saravanan | Chukwuebuka Egbuna | Horne Iona Averal
Drug Development for Cancer and Diabetes
A Path to 2030
E-Book
08/2020
1st Edition
Apple Academic Press Inc.
€184.99
Available for download
K. Saravanan | Chukwuebuka Egbuna | Horne Iona Averal
Drug Development for Cancer and Diabetes
A Path to 2030
E-Book
08/2020
1st Edition
Apple Academic Press Inc.
€184.99
Available for download
Persons
K. Saravanan, PhD, is Associate Dean of Academic Affairs and Assistant Professor of Zoology, Nehru Memorial College, an affiliated institution of Bharathidasan University, Tamilnadu, India. He has been engaged in teaching, research, and writing for over 15 years.
Chukwuebuka Egbuna is a chartered chemist, a chemical analyst, and an academic researcher. He has had many roles at New Divine Favor Pharmaceutical Industry Limited, Nigeria, and Chukwuemeka Odumegwu Ojukwu University, Nigeria. He has published research articles on phytochemistry as well as the 3-volume book Phytochemistry with AAP.
Horne Iona Averal, PhD, is Associate Professor at Holy Cross College, Trichy, India. She has received many awards and honors and has been engaged with many academic roles at several colleges and universities. Dr. Averal has published four nucleotide sequences in the NCBI-GENBANK.
S. Kannan, PhD, is a specialist in cancer biology and nanomedicine. He has held many roles at national and international academic and scientific bodies and has published a large number of research articles and books in his field.
S. Elavarasi, PhD, is Assistant Professor at Holy Cross College, an affiliated institution of Bharathidasan University, Tamilnadu, India. She has been engaged in teaching and research for more than eight years. She has published research articles, book chapters, and books.
Bir Bahadur, PhD, was formerly Professor, Chairman, and Head of the Department, as well as Dean of the Faculty of Science at Kakatiya University in Warangal, India. A prolific writer and editor, he received many awards and honors during his long career, including being named as an Eminent Botanist of India.
Chukwuebuka Egbuna is a chartered chemist, a chemical analyst, and an academic researcher. He has had many roles at New Divine Favor Pharmaceutical Industry Limited, Nigeria, and Chukwuemeka Odumegwu Ojukwu University, Nigeria. He has published research articles on phytochemistry as well as the 3-volume book Phytochemistry with AAP.
Horne Iona Averal, PhD, is Associate Professor at Holy Cross College, Trichy, India. She has received many awards and honors and has been engaged with many academic roles at several colleges and universities. Dr. Averal has published four nucleotide sequences in the NCBI-GENBANK.
S. Kannan, PhD, is a specialist in cancer biology and nanomedicine. He has held many roles at national and international academic and scientific bodies and has published a large number of research articles and books in his field.
S. Elavarasi, PhD, is Assistant Professor at Holy Cross College, an affiliated institution of Bharathidasan University, Tamilnadu, India. She has been engaged in teaching and research for more than eight years. She has published research articles, book chapters, and books.
Bir Bahadur, PhD, was formerly Professor, Chairman, and Head of the Department, as well as Dean of the Faculty of Science at Kakatiya University in Warangal, India. A prolific writer and editor, he received many awards and honors during his long career, including being named as an Eminent Botanist of India.
Content
PART I CANCER AND LEADS FOR CANCER TREATMENT 1. Biomarkers for Screening of Premalignant Lesions and Therapeutic Surveillance 2. Kinase Targets in Cancer Drug Discovery 3. Essential Drug Properties and Stages in Anti-Cancer Drug Development 4. Plant Constituent as Anti-Cancer Drugs 5. Anticancer Properties of Some Effective Phytochemicals 6. Therapeutic Aspects of Some Extracts and Purified Cardiac Glycosides Obtained From Nerium oleander L 7. Challenging Compounds of Some Medicinal Plants Against Cancer 8. Medicinal Plants as Therapeutic Agents in the Treatment of Cancer 9. Cytotoxic, Apoptosis Inducing Effects and Anti-Cancerous Drug Candidature of Jasmonates 10. Apoptosis Activity of 1,2,-Benzene Dicarboxylic Acid Isolated from Andrographis paniculata on KB, SiHa and IMR Cancer Cell Line 11. Anticancer Drug Discovery From the Indian Spice Box 12. Phytochemical Investigation and Evaluation of Anti-Breast Cancer Activity of Chloroform Extract of Tagetes erecta 13. Isolation, Identification and In Silico Evaluation of Anticancer Activity of Flavone from Pisum sativum 14. Functional Lead Phytochemicals from the Rutaceae and Zingeiberaceae Plants for Development of Anticancer Drugs 15. In Vitro Anticancer Activity of Biophytum sensitivum on Liver Cancer Lines (HEPG2) 16. Saffron and Its Active Ingredients: A Natural Product with Potent Anticancer Property PART I: ANTIDIABETIC DRUG DISCOVERY 17. Effects of Pterocarpus marsupium in the Management of Type 2 Diabetes Mellitus 18. Antidiabetic and Antihyperlipidemic Activities of Cyathea nilgiriensis (Holttum) on STZ Induced Diabetic Rats 19. Antidiabetic Activity of Drug Loaded Chitosan Nanoparticle 20. Antidiabetic Activity of Silver Nanoparticles Biosynthesized Using Ventilago maderaspatana Leaf Extract 21. Hypoglycemic Activity of Biophytum sensitivum Whole Plant Extracts on Alloxan Induced Diabetic Rats 22. Antidiabetic Activity of Ventilago maderaspatana Leaf Extracts on STZ Induced Diabetic Rats 23. Isolation, Identification, and Molecular Docking of Antidiabetic Compounds of Cyatheia nilgiriensis (Holttum) 24. Antidiabetic Potentials of Major Indian Spices: A Review 25. Aloe Species: Chemical Composition and Therapeutic Uses in Diabetic Treatment